UCB announces positive results in a trial designed for the goal of a Monotherapy Indication for Vimpat (Lacosamide)


These new data support our development of Vimpat as monotherapy for partial onset seizures and our goal to make it available to many more people living with epilepsy worldwide. UCB plans to submit these data to the U.S. Food & Drug Administration during the second half of 2013 as part of our supplemental New Drug Application for Vimpat. Vimpat is currently approved as adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy (ages ≥ 17 years). It is available in 36 countries worldwide and has been used by over 230,000 patients.



Contact Us

501-227-5061 Phone
501-227-5234 Fax
888-527-5061 Toll Free

#2 Lile Court Suite 100
Little Rock, Arkansas 72205

Little Rock Office Location